Menu

Pipeline Overview*

Pipeline Overview*

Drug** Indication Pre-clinical Phase 1/2 Phase 3 Approved
Talicia® H. pylori infection***
Approved by U.S. FDA November 2019
RHB-104 Crohn's disease
Positive top-line results from Phase 3 MAP U.S. study
RHB-204 NTM infections
Pivotal Phase 3 study planned
RHB-102
(Bekinda®)
Gastroenteritis & gastritis
Positive results from Phase 3 U.S. study
IBS-D
Positive results from Phase 2 U.S. study
RHB-106 Bowel cleanser
Phase 2/3 studies planned
Opaganib
(Yeliva®)
Oncology indications and COVID-19
Ongoing studies in cholangiocarcinoma & COVID-19
RHB-107
upamostat
Oncology/GI and COVID-19
GI, inflammatory & oncology indications
Other
RIZAPORT®
(RHB-103)
Migraine
U.S. NDA filed - re-submission of NDA planned following CRL
EUROPEAN MAA APPROVED UNDER THE EUROPEAN DECENTRALIZED PROCEDURE
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies**RHB-102 (Bekinda®) and Opaganib (Yeliva®) are proposed tradenames which are subject to FDA review and approval.